- Market Capitalization, $K 6,584,056
- Shares Outstanding, K 165,720
- Annual Sales, $ 2,225 M
- Annual Income, $ 272,000 K
- 60-Month Beta 0.22
- Price/Sales 2.97
- Price/Cash Flow 14.79
- Price/Book 3.07
|Period||Period Low||Period High||Performance|
| || |
+2.37 (+6.35%)since 10/11/19
| || |
+3.47 (+9.58%)since 08/12/19
| || |
+6.29 (+18.82%)since 11/12/18
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Dr. Reddy's (RDY) earnings and revenues increase year over year in second-quarter fiscal 2020.
Dr. Reddy's Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY) today announced its consolidated financial results for the quarter and the half year ended September 30, 2019 under International...
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries, together referred to as "Dr. Reddy's") confirms it had initiated a voluntary nationwide recall on October...
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) will announce results for the second quarter ended September 30, 2019 on Friday, November 1, 2019 after the Board Meeting.
Mylan (MYL) sinks after the SEC charges it for misclassification of EpiPen.
The Zacks Analyst Blog Highlights: Dr. Reddy's, WNS and Azure Power
BridgeBio Pharma (BBIO) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Foamix (FOMX) enrolls first patient in phase II study on its topical combination foam, FCD105, for the treatment of moderate-to-severe acne vulgaris.
The government of India unveils an array of concessions to spur the economy. This in turn will slash most corporate taxes to 22% while new manufacturers will pay even a lower corporate tax rate of 15%....